NCT04866667Completed
Observational Study of ASCVD Risks of Type 2 Diabetes in East China
Screening and Intervention of Arteriosclerotic Cardiovascular Disease in Type 2 Diabetes in Zhejiang Province
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
The aim of this study is to screen patients with type 2 diabetes with high risk of cardiovascular disease, and intervene with or without Glucagon like peptide-1 receptor agonists.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 316 (actual)
- First submitted
- 20 Apr 2021
- Start date
- 1 May 2021
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- Zhejiang Provincial People's Hospital
- Diseases
- Type 2 diabetes
- NCT number
- NCT04866667
What you commit to
- Study type: Observational
- Participants enrolled: 316
- From 1 May 2021 to the primary completion date, 31 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of a GLP-1 receptor agonist (exenatide, liraglutide or other) or pramlintide or any DPP-4 inhibitor within the 3 months prior to screening
- Use of insulin other than human NPH insulin or long-acting insulin analogue or premixed insulin within 3 months prior to screening. Shortterm use of other insulin during this period in connection with intercurrent illness is allowed, at Investigators discretion
- An acute coronary or cerebrovascular event in the previous 14 d
- Current continuous renal replacement therapy
Other illness
- Type 1 diabetes
- other type diabetes
- Chronic heart failure (NYHA class IV)
- End-stage liver disease
- History of solid organ transplant or awaiting solid organ transplant
- Malignant neoplasm
- Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC)
- Personal history of non-familial medullary thyroid carcinoma
Other
- Calcitonin ≥50 ng/L
- Acute decompensation of glycemic control
- Currently planned coronary, carotid, or peripheral artery revascularization
Who the study is looking for
- Type 2 diabetes
- HbA1c ≥7.0%
- Prior CVD cohort: age ≥50 and ≥1 of the following criteria.
- Prior MI
- Prior stroke or TIA
- Prior coronary, carotid or peripheral arterial revascularization
- N50% stenosis of coronary, carotid, or lower extremity arteries
- History of symptomatic CHD documented by Positive exercise stress test or any cardiac imaging or Unstable angina with ECG changes
- Asymptomatic cardiac ischemia Documented by positive nuclear imaging test, exercise test or dobutamine stress echo
- Chronic heart failure NYHA class II-III
- Chronic renal failure, eGFR \<60 mL/min per 1.73m2 MDRD eGFR \<60 mL/min per Cockcroft-Gault formula
- No Prior CVD group: Age ≥60 y and ≥1 of the following criteria.
- Microalbuminuria or proteinuria
- Hypertension and left ventricular hypertrophy by ECG or imaging
- Left ventricular systolic or diastolic dysfunction by imaging
- Ankle-brachial index b0.9
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhejiang Provincial People's Hospital Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.